Market Closed -
Japan Exchange
07:00:00 13/05/2024 BST
5-day change
1st Jan Change
3,150
JPY
-2.48%
-1.72%
-3.67%
Mochida Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024
February 05, 2024 at 05:00 am
Mochida Pharmaceutical Co., Ltd. provided dividend guidance for the year ending March 31, 2024. For the year end, the company expects dividend of JPY 40.00 per share as same as a year ago.
Hidehiro Imatsu named president of Goldman Sachs Japan
04-25
RE
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.
03-21
CI
Mochida Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 15, 2023, has closed with 1,080,000 shares, representing 2.97% for ¥3,485.1 million.
03-18
CI
Mochida Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024
02-05
CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
02-05
CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.
01-04
CI
Mochida Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Dividend Guidance for the Year Ending March 31, 2024
11-02
CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
11-02
CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.
02/10/23
CI
Mochida Pharmaceutical Co., Ltd. Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024
04/08/23
CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
04/08/23
CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.
03/07/23
CI
Mochida Pharmaceutical's Fiscal Full-Year Profit Falls 37.1%
16/05/23
MT
Mochida Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
15/05/23
CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
15/05/23
CI
Mochida Pharmaceutical Co., Ltd. Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024
15/05/23
CI
Mochida Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 30, 2023
15/05/23
CI
Mochida Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,080,000 shares, representing 2.96% for ¥3,500 million.
15/05/23
CI
Mochida Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
14/05/23
CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 1, 2022.
23/03/23
CI
Mochida Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 1, 2022, has closed with 1,036,200 shares, representing 2.78% for ¥3,499.72 million.
21/03/23
CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 1, 2022.
04/01/23
CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 1, 2022.
03/10/22
CI
Mochida Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,190,000 shares, representing 3.17% for ¥3,500 million.
01/08/22
CI
Mochida Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
31/07/22
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Mochida Pharmaceutical Co Ltd is a Japan-based company principally engaged in the production and sale of drugs. The Pharmaceutical-related segment is engaged in the manufacture, purchase and sale of pharmaceutical products. The Company also conducts brokerage and management of real estate properties, the maintenance and management of buildings, the agency of personal affairs, accounting and purchasing businesses. The Healthcare segment is involved in the manufacture, purchase and sale of quasi drugs and cosmetic products.
More about the company
Last Close Price
3,230
JPY
Average target price
3,200
JPY
Spread / Average Target
-0.93%
Consensus
1st Jan change
Capi.
-3.67% 735M +30.38% 684B +29.81% 568B -4.36% 361B +19.30% 329B +3.73% 284B +16.26% 240B +9.00% 208B -7.57% 200B +7.68% 166B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1